Biopharma Manufacturing for Advanced Therapies
New medicines show enormous promise, but a number of important challenges will need to be addressed
This Financial Times event, organised in partnership with Cytiva, brought together pharma, biotech, CDMOs, industry suppliers of services and equipment, and other players engaged in the fast-growing field of RNA, Cell and Gene, ATMPs manufacture and commercialisation. The focus was on innovative ways to expedite and improve biomanufacturing and ensure the next generation of advanced therapies can reach patients affordably and at scale.
Biopharma manufacturing faces challenges in scaling, personalising and speed/agility for advanced therapies.
Building a scalable ecosystem is crucial for industrialising production and bringing therapies to market.
Automation and Flexibility
Finding the right balance between automation and flexibility is key to addressing scalability and cost challenges.
World-Class Business Leaders and Speakers
Past experiences of scaling up can be applied to speed molecules to market.
Collaboration is key to success and having skilled people is essential to keep up with science.
Dialogue with regulators is important for the development of advanced therapies and the industry must help regulators become comfortable with them.
Watch now on-demand
FT Live Digital Dialogues - fully digital 50 minute event experiences delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice